NASDAQ:BMRN BioMarin Pharmaceutical (BMRN) Stock Price, News & Analysis → The Crypto 9-5 Escape Plan (From Crypto 101 Media) (Ad) Free BMRN Stock Alerts $81.72 -0.11 (-0.13%) (As of 05/9/2024 ET) Add Compare Share Share Today's Range$81.40▼$82.4150-Day Range$80.76▼$92.2252-Week Range$76.02▼$99.56Volume1.15 million shsAverage Volume1.45 million shsMarket Capitalization$15.52 billionP/E Ratio76.37Dividend YieldN/APrice Target$107.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get BioMarin Pharmaceutical alerts: Email Address BioMarin Pharmaceutical MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.63 Rating ScoreUpside/Downside31.5% Upside$107.50 Price TargetShort InterestHealthy1.94% of Shares Sold ShortDividend StrengthN/ASustainability-2.93Upright™ Environmental ScoreNews Sentiment0.64Based on 15 Articles This WeekInsider TradingSelling Shares$7.90 M Sold Last QuarterProj. Earnings Growth41.92%From $1.98 to $2.81 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.92 out of 5 starsMedical Sector24th out of 915 stocksPharmaceutical Preparations Industry8th out of 426 stocks 4.3 Analyst's Opinion Consensus RatingBioMarin Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on 12 buy ratings, 7 hold ratings, and no sell ratings.Amount of Analyst CoverageBioMarin Pharmaceutical has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about BioMarin Pharmaceutical's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.94% of the outstanding shares of BioMarin Pharmaceutical have been sold short.Short Interest Ratio / Days to CoverBioMarin Pharmaceutical has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioMarin Pharmaceutical has recently increased by 20.59%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBioMarin Pharmaceutical does not currently pay a dividend.Dividend GrowthBioMarin Pharmaceutical does not have a long track record of dividend growth. Previous Next 3.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreBioMarin Pharmaceutical has received a 35.96% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Galsulfase", "Laronidase", and "Cerliponase alfa" products. See details.Environmental SustainabilityThe Environmental Impact score for BioMarin Pharmaceutical is -2.93. Previous Next 2.6 News and Social Media Coverage News SentimentBioMarin Pharmaceutical has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for BioMarin Pharmaceutical this week, compared to 7 articles on an average week.Search InterestOnly 7 people have searched for BMRN on MarketBeat in the last 30 days. This is a decrease of -30% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added BioMarin Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is a decrease of -29% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioMarin Pharmaceutical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,896,036.00 in company stock.Percentage Held by InsidersOnly 1.85% of the stock of BioMarin Pharmaceutical is held by insiders.Percentage Held by Institutions98.71% of the stock of BioMarin Pharmaceutical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about BioMarin Pharmaceutical's insider trading history. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for BioMarin Pharmaceutical are expected to grow by 41.92% in the coming year, from $1.98 to $2.81 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioMarin Pharmaceutical is 76.37, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 137.05.Price to Earnings Ratio vs. SectorThe P/E ratio of BioMarin Pharmaceutical is 76.37, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 167.79.Price to Earnings Growth RatioBioMarin Pharmaceutical has a PEG Ratio of 1.30. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioBioMarin Pharmaceutical has a P/B Ratio of 3.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about BioMarin Pharmaceutical's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Crash Insurance” For Your RetirementWhen it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. Click here to register for free. About BioMarin Pharmaceutical Stock (NASDAQ:BMRN)BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.Read More BMRN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BMRN Stock News HeadlinesMay 7, 2024 | insidertrades.comInsider Selling: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) EVP Sells 1,850 Shares of StockApril 16, 2024 | insidertrades.comBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Director Jean Jacques Bienaime Sells 20,000 SharesMay 10, 2024 | Behind the Markets (Ad)BREAKING – Pentagon to Spend $20 Billion on “Distributed AI”BREAKING - Pentagon to Spend $20 Billion on "Distributed AI" The U.S. Space Force calls it a "game changer." And one tiny firm is poised to win the contract to build it.April 13, 2024 | insidertrades.comBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CAO Erin Burkhart Sells 2,286 SharesMay 9, 2024 | investorplace.comThe 3 Best Biotech Stocks to Buy in May 2024May 9, 2024 | americanbankingnews.comBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Receives Consensus Rating of "Moderate Buy" from BrokeragesMay 8, 2024 | prnewswire.comBioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NVMay 7, 2024 | americanbankingnews.comBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) EVP George Eric Davis Sells 1,850 Shares of StockMay 10, 2024 | Behind the Markets (Ad)The Weight Loss Pill That Could Disrupt a $32 Billion IndustryA revolutionary new weight loss pill is about to send shockwaves through the plus-size clothing market. Analysts are calling it the "King Kong" of diet drugs after amazing clinical trial results.May 6, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: RxSight (RXST) and BioMarin Pharmaceutical (BMRN)May 6, 2024 | markets.businessinsider.comBioMarin Pharmaceutical Hold Rating: Potential for Voxzogo Label Expansion Amidst Early Data and Upcoming TrialsMay 6, 2024 | finance.yahoo.comInsider Sale: EVP, Chief Commercial Officer Jeffrey Ajer Sells 5,000 Shares of Biomarin ...May 4, 2024 | prnewswire.comNew Data for BioMarin's VOXZOGO® (vosoritide) for Multiple Growth-Related Conditions in Children Presented at Pediatric Endocrine Society (PES) Annual MeetingMay 3, 2024 | investorplace.comCiti Just Cut Its Price Target on These 3 StocksApril 30, 2024 | msn.comBiotech Sector: M&A Fuels Renewed ExcitementApril 30, 2024 | finance.yahoo.comBioMarin Pharmaceutical Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This YearApril 30, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW), BioMarin Pharmaceutical (BMRN) and Hookipa Pharma (HOOK)April 29, 2024 | finance.yahoo.comBioMarin Pharmaceutical Investors Overfocused on Roctavian, Distracted From Enzyme Replacement Therapies, UBS SaysApril 27, 2024 | finance.yahoo.comBeyond the Balance Sheet: What SWOT Reveals About Biomarin Pharmaceutical Inc (BMRN)April 26, 2024 | msn.comToday's Stocks Selling Off: Intel, Biomarin, TextronApril 26, 2024 | markets.businessinsider.comBuy Rating Affirmed for BioMarin Pharmaceutical Amidst Strong Earnings and Voxzogo’s Growth PotentialApril 26, 2024 | finance.yahoo.comBioMarin Pharmaceutical First Quarter 2024 Earnings: EPS Beats ExpectationsApril 25, 2024 | finanznachrichten.deBioMarin Pharmaceutical Inc.: BioMarin Reports Record Financial Results for the First Quarter 2024April 25, 2024 | markets.businessinsider.comScotiabank Reaffirms Their Hold Rating on BioMarin Pharmaceutical (BMRN)April 25, 2024 | finance.yahoo.comQ1 2024 Biomarin Pharmaceutical Inc Earnings CallApril 25, 2024 | investorplace.com3 Biotech Stocks That Could Be Multibaggers in the Making: April EditionApril 25, 2024 | finance.yahoo.comBiomarin Pharmaceutical Inc (BMRN) Q1 2024 Earnings Call Transcript Highlights: Strong Growth ...See More Headlines Receive BMRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioMarin Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2024Today5/09/2024Next Earnings (Estimated)7/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:BMRN CUSIP09061G10 CIK1048477 Webwww.bmrn.com Phone(415) 506-6700Fax415-382-7889Employees3,401Year Founded1997Price Target and Rating Average Stock Price Target$107.50 High Stock Price Target$185.00 Low Stock Price Target$78.00 Potential Upside/Downside+31.5%Consensus RatingModerate Buy Rating Score (0-4)2.63 Research Coverage19 Analysts Profitability EPS (Most Recent Fiscal Year)$1.07 Trailing P/E Ratio76.37 Forward P/E Ratio41.27 P/E Growth1.3Net Income$167.65 million Net Margins8.31% Pretax Margin9.60% Return on Equity5.34% Return on Assets3.89% Debt Debt-to-Equity Ratio0.12 Current Ratio2.74 Quick Ratio1.70 Sales & Book Value Annual Sales$2.42 billion Price / Sales6.41 Cash Flow$1.77 per share Price / Cash Flow46.08 Book Value$26.29 per share Price / Book3.11Miscellaneous Outstanding Shares189,880,000Free Float186,367,000Market Cap$15.52 billion OptionableOptionable Beta0.34 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Alexander Hardy (Age 55)President, CEO & Director Comp: $1.72MMr. Brian R. Mueller (Age 50)CFO & Executive VP Comp: $1.07MDr. C. Greg Guyer Ph.D. (Age 62)Executive VP & Chief Technical Officer Comp: $1.11MMr. Jeffrey Robert Ajer (Age 62)Executive VP & Chief Commercial Officer Comp: $1.1MDr. Henry J. Fuchs M.D. (Age 66)Ph.D., President of Worldwide Research & Development Comp: $1.41MMs. Erin Burkhart (Age 45)Group VP & Chief Accounting Officer Dr. Kevin Eggan Ph.D.Chief Scientific Officer & Senior VP of Research and Early DevelopmentTraci McCartyGroup Vice President of Investor RelationsMr. George Eric Davis (Age 53)Executive VP, Chief Legal Officer, General Counsel & Secretary Comp: $1.23MMs. Humaira SerajuddinSenior VP & Chief Marketing OfficerMore ExecutivesKey CompetitorsMyoKardiaNASDAQ:MYOKAlnylam PharmaceuticalsNASDAQ:ALNYUnited TherapeuticsNASDAQ:UTHRReata PharmaceuticalsNASDAQ:RETAIonis PharmaceuticalsNASDAQ:IONSView All CompetitorsInsiders & InstitutionsScout Investments Inc.Sold 115,757 shares on 5/9/2024Ownership: 0.356%State Board of Administration of Florida Retirement SystemBought 2,884 shares on 5/9/2024Ownership: 0.114%Mitsubishi UFJ Asset Management Co. Ltd.Bought 23,156 shares on 5/9/2024Ownership: 0.056%Blair William & Co. ILBought 878 shares on 5/9/2024Ownership: 0.020%Orion Portfolio Solutions LLCSold 568 shares on 5/9/2024Ownership: 0.010%View All Insider TransactionsView All Institutional Transactions BMRN Stock Analysis - Frequently Asked Questions Should I buy or sell BioMarin Pharmaceutical stock right now? 19 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioMarin Pharmaceutical in the last year. There are currently 7 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BMRN shares. View BMRN analyst ratings or view top-rated stocks. What is BioMarin Pharmaceutical's stock price target for 2024? 19 analysts have issued 12-month price objectives for BioMarin Pharmaceutical's stock. Their BMRN share price targets range from $78.00 to $185.00. On average, they anticipate the company's share price to reach $107.50 in the next twelve months. This suggests a possible upside of 31.5% from the stock's current price. View analysts price targets for BMRN or view top-rated stocks among Wall Street analysts. How have BMRN shares performed in 2024? BioMarin Pharmaceutical's stock was trading at $96.42 at the start of the year. Since then, BMRN stock has decreased by 15.2% and is now trading at $81.72. View the best growth stocks for 2024 here. When is BioMarin Pharmaceutical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, July 29th 2024. View our BMRN earnings forecast. How were BioMarin Pharmaceutical's earnings last quarter? BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released its quarterly earnings results on Thursday, February, 22nd. The biotechnology company reported $0.49 earnings per share for the quarter, beating the consensus estimate of $0.45 by $0.05. The biotechnology company had revenue of $646.21 million for the quarter, compared to the consensus estimate of $639.53 million. BioMarin Pharmaceutical had a net margin of 8.31% and a trailing twelve-month return on equity of 5.34%. BioMarin Pharmaceutical's revenue was up 20.2% on a year-over-year basis. During the same period in the prior year, the business posted $0.11 EPS. What ETFs hold BioMarin Pharmaceutical's stock? ETFs with the largest weight of BioMarin Pharmaceutical (NASDAQ:BMRN) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE), Global X Genomics & Biotechnology ETF (GNOM), Simplify Health Care ETF (PINK), First Trust NYSE Arca Biotechnology Index Fund (FBT), Goldman Sachs Future Health Care Equity ETF (GDOC), VanEck Biotech ETF (BBH), BNY Mellon Innovators ETF (BKIV) and Motley Fool Mid-Cap Growth ETF (TMFM). What guidance has BioMarin Pharmaceutical issued on next quarter's earnings? BioMarin Pharmaceutical updated its FY 2024 earnings guidance on Wednesday, April, 24th. The company provided earnings per share guidance of 2.750-2.950 for the period, compared to the consensus earnings per share estimate of 1.650. The company issued revenue guidance of $2.7 billion-$2.8 billion, compared to the consensus revenue estimate of $2.8 billion. What is Jean-Jacques Bienaimé's approval rating as BioMarin Pharmaceutical's CEO? 228 employees have rated BioMarin Pharmaceutical Chief Executive Officer Jean-Jacques Bienaimé on Glassdoor.com. Jean-Jacques Bienaimé has an approval rating of 94% among the company's employees. This puts Jean-Jacques Bienaimé in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at BioMarin Pharmaceutical to a friend. What other stocks do shareholders of BioMarin Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some companies that other BioMarin Pharmaceutical investors own include Puma Biotechnology (PBYI), (MDVN) (MDVN), Incyte (INCY), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), Vertex Pharmaceuticals (VRTX), (KITE) (KITE) and Freeport-McMoRan (FCX). Who are BioMarin Pharmaceutical's major shareholders? BioMarin Pharmaceutical's stock is owned by a number of retail and institutional investors. Top institutional investors include Scout Investments Inc. (0.36%), Swiss National Bank (0.30%), Sumitomo Mitsui Trust Holdings Inc. (0.25%), Motley Fool Wealth Management LLC (0.24%), AMI Asset Management Corp (0.18%) and State Board of Administration of Florida Retirement System (0.11%). Insiders that own company stock include Brian Mueller, Charles Greg Guyer, Dennis Slamon, Erin Burkhart, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Mark J Alles, Richard A Meier and V Bryan Lawlis. View institutional ownership trends. How do I buy shares of BioMarin Pharmaceutical? Shares of BMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BMRN) was last updated on 5/10/2024 by MarketBeat.com Staff From Our PartnersThe Crypto 9-5 Escape PlanCrypto 101 MediaHe Is Giving Away BitcoinCrypto Swap ProfitsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingCharles Payne Demystifies OptionsUnstoppable ProsperityShocking: One AI startup's revenue could surge 4,735%Manward Press[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsMissed NVDA? Buy this AI stock NOWChaikin AnalyticsGold ManiaStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioMarin Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
